Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640023 | 1.00 | HTT (0.49) | HTTLMNACHRM3CHRM1CYP1A2 | |
| SCHEMBL14365561 | 0.92 | CYP1A2 (0.50) | CHRM3CHRM1CYP1A2TDP1HSD17B10 | |
| SCHEMBL2364758 | 0.92 | CYP1A2 (0.50) | CHRM3CHRM1CYP1A2TDP1HSD17B10 | |
| SCHEMBL14312045 | 0.92 | CYP1A2 (0.50) | CHRM3CHRM1CYP1A2TDP1HSD17B10 | |
| Hydrochloric Acid SCHEMBL27570937 | 0.90 | CYP1A2 (0.48) | HTTCHRM3CHRM1CYP1A2TDP1 | |
| Hydrochloric Acid SCHEMBL28730328 | 0.90 | CYP1A2 (0.48) | HTTCHRM3CHRM1CYP1A2TDP1 | |
| Hydrochloric Acid SCHEMBL6895435 | 0.90 | CYP1A2 (0.48) | HTTCHRM3CHRM1CYP1A2TDP1 | |
| Hydrochloric Acid SCHEMBL29646459 | 0.90 | CYP1A2 (0.48) | HTTCHRM3CHRM1CYP1A2TDP1 | |
| SCHEMBL14656016 | 0.88 | — | — | |
| SCHEMBL26644135 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464268-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2020-03-11 | — | — | EP | disclosed |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-01-08 | — | — | US | disclosed |
| US-20170340611-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340611-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | HTT 1999/4885LMNA 2409/4885CHRM3 4577/4885 |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | SERPINB1, ELANE, EPX | HTT 1405/4885LMNA 1808/4885CHRM3 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.